Alzheimer’s Disease/Dementia News

NEW YORK — Lithium exposure in drinking water was associated with potentially detrimental effects on human health, including increased risk for autism spectrum disorder and schizophrenia spectrum disorder, according to researchers.

DENVER — Treatment with a novel, oral receptor agonist led to rapid and significant improvements in those with agitation related to Alzheimer’s disease, according to a speaker at the American Academy of Neurology annual meeting.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

Less than optimal heart health at midlife was associated with a decline in the mental processing speed of Black women, but not white women, researchers reported.

The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.

DENVER — While rare and associated with a limited differential diagnosis, abrupt-onset dementia may be treatable with prompt recognition and early intervention, according to a poster at the American Academy of Neurology annual meeting.

DENVER – Location of residence was not associated with subjective cognitive decline in Black women, suggesting the Area Deprivation Index may not be a reliable measurement, according to a speaker.

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.